Insulet Reports Strong Q1 Results, Raises Full-Year Revenue Guidance, and Repurchases $218M in Shares

summarizeSummary

Insulet Corporation announced robust first-quarter results, exceeding revenue guidance, and raised its full-year revenue outlook. The company also reported a significant share repurchase of 1.25 million shares.

check_boxKey Events

• Strong Q1 Financial Performance

  Revenue of $761.7 million, up 33.9% year-over-year, exceeded the high end of the company's guidance range. Net income per diluted share was $1.30, with adjusted EPS at $1.42.

• Raised Full-Year Revenue Guidance

  Insulet increased its full-year 2026 total company revenue growth outlook to 21%-23% (constant currency), up from the prior guidance of 20%-22%.

• Significant Share Repurchase

  The company repurchased 1.25 million shares of common stock, representing a substantial return of capital to shareholders, valued at approximately $218.7 million based on today's stock price.

• Product Expansion & Innovation

  Launched Omnipod 5 in five new Middle East countries and advanced development of a fully closed-loop AID system for type 2 diabetes, including enrolling the first participant in the EVOLVE pivotal study.

auto_awesomeAnalysis

Insulet's Q1 2026 performance demonstrates strong operational execution, with revenue significantly surpassing expectations and a notable increase in profitability. The decision to raise full-year revenue guidance signals management's increased confidence in sustained growth. Furthermore, the substantial share repurchase of 1.25 million shares, valued at approximately $218.7 million, indicates a commitment to returning capital to shareholders and a belief in the company's intrinsic value. This filing provides official confirmation and detailed financial context to the strong Q1 results previously reported by Reuters, with the guidance raise being a key new positive development.